Gene therapy using the herpes simplex virus thymidine kinase (HSV-TK) gene in combination with the drug ganciclovir (GCV) is a promising approach for the treatment of cancer-inducing gliomas, a tumor with a poor prognosis. In an attempt to limit the toxic effects on normal tissues, we constructed a recombinant adenoviral vector, Adgfa2TK, in which the HSV-TK gene is driven by the promoter for the gene encoding glial fibrillary acidic protein, an intermediate filament protein expressed primarily in astrocytes. Infection by Adgfa2TK of a glial cell line (C6) and a non-glial cell line (MDA-MB-231) revealed markedly increased expression of HSV-TK in glial cells as determined by Western blot. In comparison, high HSV-TK protein levels were produced in both cell lines after infection with a control virus, AdCMVTK, in which the constitutive cytomegalovirus viral promoter was used to direct HSV-TK expression. Infection of two glial cell lines (C6, U251) and two non-glial cell lines (HepG2, MDA-MB-231) with Adgfa2TK followed by GCV treatment revealed high toxicity in glial cell lines (50% growth inhibitory concentration: Ͻ2 g/mL of GCV) with little or no toxicity (50% growth inhibitory concentration: Ͼ75 g/mL) in the non-glial cell lines. In vivo, injection of Adgfa2TK into C6 tumors grown in nude mice followed by intraperitoneal GCV treatment significantly repressed tumor growth compared with the controls. Adgfa2TK may be useful for directing expression of the HSV-TK gene to gliomas.
G lioblastomas account for 20% of primary brain tumors in adults. Despite advances in surgery, radiotherapy, and chemotherapy, the prognosis of patients with glioblastoma remains grim, with a median survival of ϳ11 months. Gene therapy represents a new approach in the treatment of cancer, including central nervous system (CNS) tumors. 1 One form of gene therapy uses a suicide gene such as the herpes simplex virus thymidine kinase (HSV-TK) gene, which metabolically activates ganciclovir (GCV) into its toxic triphosphate form. 2 Cells undergoing division are killed when this nucleotide analog is incorporated into DNA. As with current modes of therapy, the primary goal of this strategy must be eradication of tumor cells while minimizing toxicity to normal tissues. Achieving maximal systemic therapeutic effects with suicide gene therapy will require administration or targeting of the genes to local tumors as well as selective delivery or expression of the suicide gene to all distant tumor sites.
Cell-specific gene targeting could be obtained by using a vector that is designed to enter a particular cell type or a vector driving the expression of the transgene in a cell-specific manner. For example, retroviral vectors stably transduce only actively dividing cells; because tumor cells have increased growth rates relative to nondividing normal cells, retroviral vectors should have preferential effects on cycling tumor cells versus quiescent cells. However, a disadvantage of retroviral vectors is that titers are generally not high, thus limiting the number of tumors cells that can be transduced in vivo. In contrast to retroviruses, adenoviruses can be produced with high titers but can infect both dividing and nondividing cells.
Another approach to tumor targeting is to place the expression of a toxic gene under the control of a cell-specific promoter. For example, the ␣-fetoprotein promoter has been used to target hepatocarcinoma cells, 3 the tyrosinase promoter has been used to target melanocytes, 4 ERBB2 and muc1 promoters have been used to preferentially target transgene expression in breast cancer cells, 5 and the carcinoembryonic antigen gene promoter has been used to target carcinoembryonic antigen-producing adenocarcinoma of the lung. 6 A cell-specific promoter of interest for selective transgene expression in astrocytes is the glial fibrillary acidic protein (GFAP) gene; GFAP encodes an intermediate filament protein expressed almost exclusively in astrocytes and is frequently expressed in gliomas. 7 Several recent studies have in fact demonstrated that a GFAP promoter fragment can induce specific expression of a transgene in glial cells compared with non-glial cells (neuroblastoma, fibroblast, epithelial cell line) and can limit expression of a toxic protein in glial cells after systemic administration. 8, 9 In this study, we investigated the use of a 2.2-kb human GFAP promoter fragment, gfa2, to target HSV-TK expression in gliomas using a high-titer recombinant adenovirus. The gfa2 promoter was selected for use as it has previously been shown to effectively express genes specifically in astrocytes, 10 including expression of HSV-TK in cultured glioma cells 11 and in astrocytes in transgenic mice. 12 The cytotoxic effects of Adgfa2TK were compared with that of a control virus, AdCMVTK, in which HSV-TK expression was controlled by the constitutive cytomegalovirus (CMV) viral promoter. We report that the toxicity of Adgfa2TK was highly specific to glioma cells, and similar in strength to that produced by AdCMVTK. Thus Adgfa2TK may be of interest for reducing problems of adventitious expression in nontarget cells when treating gliomas.
MATERIALS AND METHODS

Cells
The rat C6 glioma cell line (American Type Culture Collection (ATCC), Manassas, Va), human U251 glioma cell line (a gift of Dr. X. Collet, Institut National de la santé et de la Recherche Médicale, Toulouse, France), human MDA-MB-231 breast cancer cells (HTB26; ATCC), human HepG2 hepatocellular carcinoma cells (ATCC), and 293A embryonic kidney cells (Quantum, Biotechnologies, Laval, Quebec, Canada), were cultured in improved minimal essential medium (IMEM) containing 10% fetal calf serum (FCS) (Life Technologies, Gaithersburg, Md).
Construction of adenoviral vectors and infection procedure
Adgfa2TK and AdCMVTK were constructed by cotransfection of the shuttle vectors sGfa2TK and sCMVTK containing the gfa2TK and CMVTK cDNA expression cassettes, respectively, and ClaI-cut genomic adenoviral DNA (Ad5CMVlacZE1/E3; Quantum Biotechnologies). The shuttle vectors sGfa2TK and sCMVTK were constructed by excision of the 4.07-kb BglIINotI fragment containing the gfa2TK coding region from the plasmid pGfa2TK 11 and the 2.5-kb BglII-NotI fragment containing the CMVTK coding region from the plasmid pCD3TK. 11 These fragments were ligated to the 5.4-kb BglIINotI-digested pQBI-AdBN transfer vector (Quantum). After cotransfection of each shuttle vector and genomic adenoviral DNA into the adenovirus-transformed human embryonic kidney cell line 293A by calcium phosphate-mediated gene transfer (Life Technologies), plaques were screened for the presence of TK sequences by polymerase chain reactions using the following set of primers: 5Ј-CGGTCCTCACGGGATGGG-GAAAACCACCACCACG-3Ј (sense) and 5Ј-GCAGGGCG-TCCCGGCAGCCGGCGGGCGATTGG-3Ј (antisense). 13 Virus from a plaque containing TK sequences was grown in 293A cells and purified by two rounds of CsCl gradient centrifugation as described previously. 14 We used an Adnull, an adenoviral vector that contains no insert and is replication-deficient, as a negative control for TK expression. 14 
Cytotoxicity assay
For cytotoxicity assays, cells were plated in triplicate in 96-well dishes (500 cells/well) and incubated for 24 hours at 37°C in IMEM containing 10% FCS. Recombinant adenoviruses (Adgfa2TK and AdCMVTK) were added to cells at various multiplicities of infection (MOIs), incubated in serum-free IMEM for 2 hours, and replaced by IMEM containing 10% FCS. GCV (Roche Laboratories, Nutley, NJ) was reconstituted in sterile water and diluted to the required concentration in complete medium immediately before use. GCV (0 -600 g/mL) was added to cells 2 hours after addition of adenoviral vectors at same time as the FCS. Cells were incubated for 4 days at 37°C, and the relative survival was estimated using a colorimetric assay performed as described previously. 15 Briefly, cells were fixed in 10% trichloroacetic acid for 1 hour, washed five times with water, and allowed to air dry. Cells were then stained for 10 minutes with 0.4% sulforhodamine B (Sigma, St. Louis, Mo) dissolved in 1% acetic acid and rinsed five times with 1% acetic acid. Absorbance (A 564 ) was determined using a BioKinetics Reader EL340 (Bio-Tek Instruments, Winnoski, Vt). The 50% growth inhibitory concentration (IC 50 ) (dose that inhibits cell growth by 50%) was calculated assuming the survival rate of uninfected and non-GCV treated cells to be 100%.
Western blot analysis
Cells (1 ϫ 10 6 ) were plated in 10-cm dishes and infected with adenovirus vectors as described above. Cell were harvested 24 hours after infection by gentle scraping. Cell lysates were subjected to Western blot analysis as described previously.
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Blots were probed with 5 g/mL monoclonal antibody directed against HSV-TK provided by Dr. William Summers (Yale University, New Haven, Conn). Blots were washed with phosphate-buffered saline (PBS) containing 0.1% Tween 20 and incubated with horseradish peroxidase conjugated to secondary antibody; specific complex was detected by the enhanced chemiluminescence technique according to the manufacturer's directions (ECL Western blotting products, Amersham, Little Chalfont, UK). To quantitate levels of HSV-TK, Western blot images were scanned and subjected to densitometric analyses using National Institutes of Health Image software.
Nude mice studies
C6 cells (5 ϫ 10 6 ) were injected into 6-week-old nude mice (nu/nu strain). After 10 days, palpable tumors were formed.
Tumors were injected with Adgfa2TK (100 L/injection, 5 ϫ 10 8 plaque-forming units (PFU) each injection) once on 2 successive days, and GCV was administered intraperitoneally (i.p.) as described in the legend to Figure 4 . The tumors were measured with calipers in two perpendicular diameters by an investigator without knowledge of the treatment groups. Tumor volumes were calculated by assuming a spherical shape, with the average tumor diameter calculated as the square root of the product of cross-sectional diameters.
Statistics
Numerical data were expressed as the mean Ϯ SEM for triplicate samples. Statistical differences between means for groups were evaluated with GraphPad Prism 2.01 software (Graphpad Software, San Diego, Calif) using a Mann-Whitney nonparametric test with the level of significance at P Ͻ .05.
RESULTS
Adenovirus vectors containing HSV-TK cDNA driven by gfa2 or CMV promoter
To investigate the efficiency and the specific expression of a gfa2-TK transgene when delivered by an adenovirus vector, two recombinant viruses were constructed. The vector Adgfa2TK uses the gfa2 promoter to drive HSV-TK, whereas the positive control vector, AdCMVTK, uses the constitutive CMV promoter. Schematic diagrams of these two adenoviruses are shown in Figure 1 . GCV sensitivity of C6, U251, MDA-MB-231, and HepG2 cells The toxicity of the Adgfa2TK and AdCMVTK viruses was determined for four cell lines originating from different tissues: C6 from a rat glioma, U251 from a human glioma, MDA-MB-231 from a human breast cancer, and HepG2 from a human hepatocellular carcinoma. Because infection with adenovirus alone can be toxic, we first determined the effects of exposing each cell line to different titers of each virus in the absence of GCV. Both viruses exhibited toxicity in each of the cell lines only at an MOI of Ͼ200 PFU/cell (data not shown). Thus, to test the toxicity due to TK expression, the cell lines were infected at an MOI of 100 PFU/cell, which is nontoxic in the absence of GCV. As another control, the sensitivity of each cell line to GCV was tested in the absence of viral infection. Incubation of cells with GCV Figure 1 . Diagrams of AdCMVTK and Adgfa2TK vectors. Viruses were constructed as described in Materials and Methods. Both viruses are replication-defective due to absence of the viral E1 region and part of the E3 region, and both contain the HSV-TK coding region under the control of the CMV or gfa2 promoter. Ad5, human adenovirus type 5; CMV, CMV major immediate early promoter; gfa2, GFAP promoter.
alone, without viral infection, induced no toxicity at doses of Ͻ100 g/mL, and the IC 50 to GCV alone was ϳ300 g/mL for each cell line examined (data not shown). 
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When the C6 glioma cell line was infected at 100 PFU/cell with Adgfa2TK or AdCMVTK, incubation with GCV at 1 g/mL produced ϳ80% and 90% cytotoxicity, respectively (Fig 3A) . Similarly when U251 human glioma cells were infected with Adgfa2TK or AdCMVTK at 100 PFU/cell, incubation with GCV at 10 g/mL produced Ͼ80% and 90% cytotoxicity, respectively (Fig 3B) . However, when two non-glial cell lines, HepG2 human hepatocellular carcinoma cells or MDA-MB-231 human breast cancer cells, were infected with Adgfa2TK and exposed to 1 g/mL GCV, there was no significant cytotoxicity (Fig 3, C and D) . In contrast, after infection with the AdCMVTK vector, in which the TK gene is driven by a constitutive viral promoter, exposure to 1 g/mL GCV produced significant toxicity in each of the non-glial cell lines (Fig 3C) . For C6 and U251 cells infected with Adgfa2TK, the IC 50 s for GCV were Ͻ0.5 g/mL (Fig 3A) and Ͻ2 g/mL (Fig 3B) , respectively. In contrast, after incubation of HepG2 human hepatocellular carcinoma cells and MDA-MB-231 human breast cancer cells with Adgfa2TK, the IC 50 for GCV in both cell lines was Ͼ75 g/mL (Fig 3, C and  D) . Thus, infection of the glioma cell lines C6 and U251 with Adgfa2TK resulted in a 150-fold and 37-fold greater sensitivity to GCV, respectively, relative to the non-glial cells.
AdGFAPTK-mediated tumor regression in vivo
To determine the effectiveness of the Adgfa2TK vector on glioma cells in vivo, tumors were produced in 6-weekold nude mice by subcutaneous injection of 5 ϫ 10 6 C6 cells. Treatment day 0 commenced 10 days later, by which time palpable tumors had formed. At this time, the established C6 tumors were injected with 5 ϫ 10 8 PFU of Adgfa2TK in 100 L of PBS (groups 1 and 2) or with PBS alone (groups 3 and 4) (n ϭ 5 for each group). These injections were then repeated 24 hours later (day 1). Beginning with these second injections, mice in groups 1 and 3 received 100 mg/kg GCV i.p. daily for 7 days; mice in groups 2 and 4 received 100 L of PBS i.p. The mice in each group appeared to be in good health over the entire treatment period. The sizes of the tumors were measured with calipers at days 0, 2, 4, 6, and 8, and their volumes were calculated by assuming a spherical shape. As shown in Figure 4 , tumors in the PBS control group of mice increased by 90% during the 8-day course of treatment. Tumor volume increased to a similar extent in the mice that received the AdgfaTK alone (group 2) or GCV alone (group 3). In sharp contrast, the tumors in the mice that received both Adgfa2TK and GCV (group 1) showed no substantial growth after treatment, such that by days 6 and 8 the average tumor volume of animals treated with the combination therapy was significantly different from that of the PBS controls (P Ͻ .05).
DISCUSSION
Although several studies have demonstrated marked in vitro cytotoxic effects of HSV-TK against glioblastoma cells, 16 successful in vivo gene therapy requires a high efficiency of transfection and increased expression of the transgene in the tumor tissues. 17 In efforts to improve the transduction efficiency, several viral and nonviral vectors have been developed. In recent phase I/II clinical studies, the problem of low titers of retroviral vectors was addressed by using HSV-TK retrovirus-producing cell lines. Injection of these HSV-TK vector-producing cells into the tumors of patients with glioblastoma was followed by systemic treatment with GCV. Although this approach has proven to be safe and results in little toxicity, the efficacy of this therapy is not clear. Klatzmann et al 18 and Berger et al 19 reported therapeutic responses using HSV-TK vector-producing cells, whereas Shand et al 20 and Laske et al 21 found only marginal benefits.
Adenoviral vectors have the advantage of being able to be produced in high titers and can infect both nondividing and dividing cells. Furthermore, adenoviral vectors expressing herpes TK driven by constitutive promoters have shown promising efficiencies both in vitro and in animals, 22, 23 and a clinical trial using AdHS-VTK in patients with CNS malignancies has been initiated. 24 Although studies by Dewey et al 25 showed growth inhibition of syngeneic glioma after intratumoral injection of an adenoviral vector expressing HSV-TK (AdHS-VTK) in combination with systemic GCV treatment, these investigators also observed active inflammation in the brain 3 months after injection of recombinant AdHSVTK. The use of an astrocyte-specific promoter could possibly reduce the host's immune response in the CNS to the transgene, as suggested by studies using intrahepatic injection of adenoviral vectors. Because adenoviral vectors infect both dividing and nondividing cells, we have attempted to improve the safety of the adenovirus-TK system by targeting expression of the suicide gene to astrocytic cells using the promoter of the gene encoding GFAP, a major component of intermediate filaments in astrocytes 27 that is not significantly expressed in any other CNS cell type. 28, 29 Previous studies have demonstrated that GFAP is a useful marker for determining the astroglial origin of tumors.
7 A 2.2-kb 5Ј-flanking region of the GFAP gene, the gfa2 promoter, has been shown to contain elements involved in astrocyte-specific expression. 30 We have shown previously that cells expressing GFAP can be sensitized to GCV after transfection of a plasmid in which the HSV-TK gene was driven by the gfa2 promoter. 11 In this report, we describe the construction of a recombinant adenoviral vector that uses the gfa2 promoter to target HSV-TK toxicity to astrocytes. Infection of Adgfa2TK at 20 PFU/cell resulted in high levels of TK protein expression in C6 glioma cells with little or no detectable expression in MDA-MB-231 breast cancer cells. Even when the MOI was increased to 200 PFU/ cell, the level of TK protein in MDA-MB-231 breast cancer cells was Ͼ10-fold lower than that in C6 cells. This difference in specificity of HSV-TK targeting resulted in marked differences in cytotoxicity after exposure to GCV. After infection of C6 and U251 glioma cells with 100 PFU/cell Adgfa2TK, the IC 50 s for GCV were Ͻ0.5 g/mL and Ͻ2 g/mL respectively. The higher sensitivity of C6 to GCV (0.5 g/mL) compared with 2 g/mL for U251 cells may be attributed to its shorter doubling time. 11 In contrast, MDA-MB-231 breast cancer cells and HepG2 hepatocarcinoma cells remained highly resistant to Adgfa2TK (IC 50 of Ͼ75 g/mL). The difference in the specificity of HSV-TK is not due to an intrinsic resistance of the non-glial cell lines to HSV-TK and GCV, as all cell lines were equally susceptible to infection with the AdCMVTK positive control vector.
Previous studies have indicated that treatment of brain tumors (or other tumors) with recombinant adenovirus may result in gene transfer into liver cells secondary to hematogenous spread. 9 Thus, the results obtained after infection of HepG2 hepatocellular carcinoma cells by Adgfa2TK are of particular interest. After infection with Adgfa2TK, this cell line showed no sensitivity to up to 50 g/mL GCV, whereas infection with AdCMVTK resulted in 80% toxicity after exposure to 50 g/mL GCV.
When Adgfa2TK is injected into the CNS, HSV-TK should be expressed in normal astrocytes as well as in GFAP-positive tumor cells. However, normal astrocytes are unlikely to be significantly affected, as observations in gfa2-TK transgenic mice indicate that the low rate of astrocyte cell division in adult animals renders them highly resistant to GCV treatment. 12 In the studies reported here, treatment with Adgfa2TK and GCV inhibited the growth of C6 tumors, but complete eradication of tumors was not observed.
These results demonstrate that the gfa2 promoter has sufficient activity to produce significant antitumoral effects, but that improvements will be necessary to improve therapeutic efficacy. In this feasibility study, only a single treatment protocol was tested for delivery of the Adgfa2TK virus and subsequent GCV treatment; thus, it is possible that an alternative protocol may produce better results. In addition, we are testing the activities of variants of the gfa2 promoter designed to have increased transcriptional activity. However, the studies in this report indicate that damage to non-glial cells can be achieved by targeting suicide gene expression to gliomas using the GFAP promoters, and that this approach to treatment of gliomas deserves further study.
